EMA — authorised 25 June 2020
- Marketing authorisation holder: Celgene Europe B.V.
- Status: approved
🇪🇺 Reblozyl in European Union
EMA authorised Reblozyl on 25 June 2020
Marketing authorisation
Reblozyl in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in European Union
Frequently asked questions
Is Reblozyl approved in European Union?
Yes. EMA authorised it on 25 June 2020.
Who is the marketing authorisation holder for Reblozyl in European Union?
Celgene Europe B.V. holds the EU marketing authorisation.